Your browser doesn't support javascript.
loading
Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry.
Figueroa, Jonine D; Middlebrooks, Candace D; Banday, A Rouf; Ye, Yuanqing; Garcia-Closas, Montserrat; Chatterjee, Nilanjan; Koutros, Stella; Kiemeney, Lambertus A; Rafnar, Thorunn; Bishop, Timothy; Furberg, Helena; Matullo, Giuseppe; Golka, Klaus; Gago-Dominguez, Manuela; Taylor, Jack A; Fletcher, Tony; Siddiq, Afshan; Cortessis, Victoria K; Kooperberg, Charles; Cussenot, Olivier; Benhamou, Simone; Prescott, Jennifer; Porru, Stefano; Dinney, Colin P; Malats, Núria; Baris, Dalsu; Purdue, Mark P; Jacobs, Eric J; Albanes, Demetrius; Wang, Zhaoming; Chung, Charles C; Vermeulen, Sita H; Aben, Katja K; Galesloot, Tessel E; Thorleifsson, Gudmar; Sulem, Patrick; Stefansson, Kari; Kiltie, Anne E; Harland, Mark; Teo, Mark; Offit, Kenneth; Vijai, Joseph; Bajorin, Dean; Kopp, Ryan; Fiorito, Giovanni; Guarrera, Simonetta; Sacerdote, Carlotta; Selinski, Silvia; Hengstler, Jan G; Gerullis, Holger.
Affiliation
  • Figueroa JD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Usher Institute of Population Health Sciences and Informatics, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK, jonine.figueroa@ed.ac.uk.
  • Middlebrooks CD; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Banday AR; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Ye Y; Department of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA.
  • Garcia-Closas M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
  • Chatterjee N; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Koutros S; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Kiemeney LA; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Rafnar T; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Bishop T; Section of Epidemiology and Biostatistics.
  • Furberg H; Department of Epidemiology and Biostatistics.
  • Matullo G; Department of Medical Sciences, University of Turin, Turin, Italy, Human Genetics Foundation, Turin, Italy.
  • Golka K; Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
  • Gago-Dominguez M; Genomic Medicine Group, Galician Foundation of Genomic Medicine, Servicio Galego de Saude (SERGAS), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.
  • Taylor JA; Epidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Research Triangle Park, NC, USA.
  • Fletcher T; London School of Hygiene and Tropical Medicine, London, UK.
  • Siddiq A; School of Public Health.
  • Cortessis VK; Department of Preventive Medicine, USC Keck School of Medicine, Department of Obstetrics and Gynecology, Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Kooperberg C; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Cussenot O; Department of Urology, Tenon, Centre de Recherche sur les Pathologies Prostatiques, Paris, France, UPMC Univ Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France.
  • Benhamou S; Institut national de la sante et de la recherche medicale, U946, Foundation Jean Dausset Centre d'Etude du Polymorphisme Humain (CEPH), Paris, France, Centre National de la Receherche Scientifique, UMR8200, Institut Gustave-Roussy, Villejuif, France.
  • Prescott J; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Department of Epidemiology.
  • Porru S; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
  • Dinney CP; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
  • Malats N; Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Baris D; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Purdue MP; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Jacobs EJ; Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
  • Albanes D; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Wang Z; Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD, USA.
  • Chung CC; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA, Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.
  • Vermeulen SH; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Aben KK; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Galesloot TE; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Thorleifsson G; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Sulem P; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
  • Stefansson K; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Kiltie AE; CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK.
  • Harland M; Section of Epidemiology and Biostatistics.
  • Teo M; Radiotherapy Research Group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK.
  • Offit K; Department of Medicine.
  • Vijai J; Department of Medicine.
  • Bajorin D; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine.
  • Kopp R; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Fiorito G; Department of Medical Sciences, University of Turin, Turin, Italy, Human Genetics Foundation, Turin, Italy.
  • Guarrera S; Department of Medical Sciences, University of Turin, Turin, Italy, Human Genetics Foundation, Turin, Italy.
  • Sacerdote C; Cancer Epidemiology, CPO Piemonte, Turin, Italy.
  • Selinski S; Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
  • Hengstler JG; Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.
  • Gerullis H; University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany, Department of Urology, Lukasklinik Neuss, Germany.
Hum Mol Genet ; 25(6): 1203-14, 2016 Mar 15.
Article in En | MEDLINE | ID: mdl-26732427
ABSTRACT
Candidate gene and genome-wide association studies (GWAS) have identified 15 independent genomic regions associated with bladder cancer risk. In search for additional susceptibility variants, we followed up on four promising single-nucleotide polymorphisms (SNPs) that had not achieved genome-wide significance in 6911 cases and 11 814 controls (rs6104690, rs4510656, rs5003154 and rs4907479, P < 1 × 10(-6)), using additional data from existing GWAS datasets and targeted genotyping for studies that did not have GWAS data. In a combined analysis, which included data on up to 15 058 cases and 286 270 controls, two SNPs achieved genome-wide statistical

significance:

rs6104690 in a gene desert at 20p12.2 (P = 2.19 × 10(-11)) and rs4907479 within the MCF2L gene at 13q34 (P = 3.3 × 10(-10)). Imputation and fine-mapping analyses were performed in these two regions for a subset of 5551 bladder cancer cases and 10 242 controls. Analyses at the 13q34 region suggest a single signal marked by rs4907479. In contrast, we detected two signals in the 20p12.2 region-the first signal is marked by rs6104690, and the second signal is marked by two moderately correlated SNPs (r(2) = 0.53), rs6108803 and the previously reported rs62185668. The second 20p12.2 signal is more strongly associated with the risk of muscle-invasive (T2-T4 stage) compared with non-muscle-invasive (Ta, T1 stage) bladder cancer (case-case P ≤ 0.02 for both rs62185668 and rs6108803). Functional analyses are needed to explore the biological mechanisms underlying these novel genetic associations with risk for bladder cancer.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Chromosomes, Human, Pair 13 / Chromosomes, Human, Pair 20 / White People Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Female / Humans / Male Language: En Journal: Hum Mol Genet Journal subject: BIOLOGIA MOLECULAR / GENETICA MEDICA Year: 2016 Document type: Article Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Chromosomes, Human, Pair 13 / Chromosomes, Human, Pair 20 / White People Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Female / Humans / Male Language: En Journal: Hum Mol Genet Journal subject: BIOLOGIA MOLECULAR / GENETICA MEDICA Year: 2016 Document type: Article Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM